



ATC codes: **L01BC05**

Indication	Other specified carcinomas of ovary <span style="float: right;">ICD11 code: <b>2D23.0Y</b></span>
INN	Gemcitabine
Medicine type	Chemical agent
List type	Complementary
Formulations	Parenteral > General injections > IV: 200 mg in vial powder for injection ; 1 g in vial powder for injection
EML status history	First added in 2015 ( <b>TRS 994</b> )
Sex	All
Age	Adolescents and adults
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> . 

Tags

Cancer

Wikipedia

[Gemcitabine](#) 

DrugBank

[Gemcitabine](#) 

### Summary of evidence and Expert Committee recommendations

In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, gemcitabine was added to the complementary list of the EML for use in treatment protocols for epithelial ovarian cancer. The relevant extract from TRS994 regarding the Expert Committee's consideration of treatment protocols for epithelial ovarian cancer is attached.

[Expert Committee report](#) 

